| Literature DB >> 31413644 |
Iman A Basheti1, Yara B Salhi1, Mariam M Basheti2, Salim A Hamadi3, Walid Al-Qerem4.
Abstract
INTRODUCTION: Pharmacists can have a valuable role in educating patients on correct inhaler technique leading to improved asthma management. Rural areas can benefit from the role of the pharmacist considering the barriers found in attending primary health-care facilities.Entities:
Keywords: asthma control; inhaler technique; pharmacist role; reliever use; rural area
Year: 2019 PMID: 31413644 PMCID: PMC6662524 DOI: 10.2147/CPAA.S213271
Source DB: PubMed Journal: Clin Pharmacol ISSN: 1179-1438
Inhaler technique checklists
| Step. Description/action |
|---|
| Turbuhaler Technique Checklist |
| 1. Remove the cap from the inhalera |
| 2. Keep inhaler uprighta |
| 3. Rotate grip until a click is hearda |
| 4. Exhale to residual volume |
| 5. Exhale away from mouthpiece |
| 6. Place mouthpiece between teeth and lips |
| 7. Inhale forcefully and deeplya |
| 8. Hold breath for 5 secondsb |
| 9. Exhale away from mouthpiece |
| Metered dose inhaler Technique Checklist |
| 1. Remove mouthpiece cover and shakea |
| 2. Hold inhaler upright |
| 3. Exhale to residual volume |
| 4. Keep head upright or slightly tilted |
| 5. Place mouthpiece between teeth and lips |
| 6. Inhale slowly and press canistera |
| 7. Continue slow and deep inhalationa |
| 8. Hold breath for 5 seconds |
| 9. Close the inhaler |
Notes: These checklists and essential steps are in accordance to the literature.17,18,34 aEssential step: if not performed correctly, little/no medication will reach the lung.16 bThis step is not included in the product insert but appears in the turbuhaler instructions on the Global Initiative for Asthma website,1 and in the checklist from van der Palen et al.18
Figure 1CONSORT diagram showing patient recruitment and retention in the study.
Abbreviations: MDI, metered dose inhaler; TH, turbuhaler.
Baseline demographic and asthma-related characteristics for TH (n=44) and MDI (n=59) users
| Variable | TH (n=44) | MDI (n=59) | All (n=103) | |
|---|---|---|---|---|
| Age (years), mean (SD) | 45.57 (12.68) | 47.20 (14.16) | 46.46 (13.50) | 0.394 |
| Gender (females), n (%) | 34 (77.3%) | 42 (71.2%) | 76 (73.8%) | 0.508 |
| Number of family members, n (%) | 0.512 | |||
| 0–3 | 7 (15.9%) | 10 (16.9%) | 17 (16.5%) | |
| 4–7 | 14 (31.8%) | 19 (32.2%) | 33 (32.0%) | |
| 8–11 | 14 (31.8%) | 12 (20.3%) | 26 (25.2%) | |
| 12–16 | 9 (20.5%) | 18 (30.5%) | 27 (26.2%) | |
| Education level, n (%) | 0.706 | |||
| Elementary school | 23 (52.3%) | 37 (62.7%) | 60 (58.3%) | |
| High school | 13 (29.5%) | 15 (25.4%) | 28 (27.2%) | |
| College | 4 (9.1%) | 3 (5.1%) | 7 (6.8%) | |
| University | 4 (9.1%) | 4 (6.8%) | 8 (7.8%) | |
| Marital status, n (%) | 28:6:2:8 | 52:3:2:2 (80.1:5.1:3.4:3.4) | 80:9:4:10 | 0.020 |
| Working status, n (%) | 0.363 | |||
| Employed | 8 (18.2%) | 13 (22%) | 21 (20.4%) | |
| Student | 2 (4.5%) | 2 (3.4%) | 4 (3.9%) | |
| Unemployed | 30 (68.2%) | 43 (72.9%) | 73 (70.9%) | |
| Retired | 4 (9.1%) | 1 (1.7%) | 5 (4.9%) | |
| Smoking status, n (%) | 30:6:8 | 38:8:13 | 68:14:21 | 0.888 |
| Duration of preventer use (years), mean (SD) | 11.70 (9.7%) | 12.41 (10.7%) | 12.1 (10.3%) | 0.838 |
| Asthma characteristics | ||||
| Onset of asthma, n (%) | 0:11:33 | 2:7:50 | 2:18:83 | 0.118 |
| Age of onset of asthma (years), mean (SD) | 31.50 (15.72) | 32.68 (14.06) | 32.5 (15.1) | 0.105 |
| Asthma control, n (%)a | 1:10:33 | 1:10:48 | 2:20:81 | 0.739 |
| ACT score, mean (SD)a | 11.43 (4.24) | 9.86 (4.26) | 10.53 (4.29) | 0.877 |
| Reliever puffs/day, mean (SD) | 4.38 (4.32) | 5.60 (4.03) | 5.1 (4.2) | 0.461 |
| FEV1% at baseline, mean (SD) | 54.57 (19.47) | 54.20 (17.87) | 54.36 (18.47) | 0.922 |
Notes: aAsthma Control Test (ACT) scores out of 25; ≥20, well-controlled asthma; 16–19, moderately controlled asthma; ≤15, very poorly controlled asthma.44
Abbreviations: FEV1%, forced expiratory volume in the first 1 second; MDI, metered dose inhaler; TH, turbuhaler.
Comparing study outcomes (inhaler technique, FEV1%, ACT, and reliever use) at baseline and end of study for study patients
| Variable | Baseline (n=103) | End of study (n=103) | |
|---|---|---|---|
| Inhaler technique score, mean (SD) | |||
| TH (n=44), score out of 9 | 5.48 (SD=1.97) | 7.39 (SD=1.19) | <0.001 |
| MDI (n=59), score out of 9 | 5.24 (SD=2.00) | 6.85 (SD=1.36) | <0.001 |
| All (n=103) | 5.34 (SD=1.98) | 7.08 (SD=1.31) | <0.001 |
| 0.546 | 0.038 | ||
| Inhaler essential technique score, mean (SD) | |||
| Correct inhaler technique, n (%) | |||
| TH (n=44) | 1 (2.27%) | 14 (31.82%) | <0.001 |
| MDI (n=59) | 0 (0.00%) | 15 (25.42%) | NA |
| All (n=103) | 1 (0.97%) | 29 (28.16%) | <0.001 |
| 0.245 | 0.475 | ||
| Correct essential technique, n (%) | |||
| TH (n=44) | 3 (6.82%) | 23 (52.27%) | <0.001 |
| MDI (n=59) | 4 (6.78%) | 24 (40.68%) | <0.001 |
| All (n=103) | 7 (6.80%) | 47 (45.63%) | <0.001 |
| 0.994 | 0.243 | ||
| FEV1%a | |||
| TH (n=44, n=27) | 54.57 (SD=19.47) | 59.52 (SD=20.20) | 0.097 |
| MDI (n=59, n=37) | 54.20 (SD=17.87) | 60.16 (SD=21.60) | 0.005 |
| All (n=103, n=64) | 54.36 (SD=18.47) | 59.89 (SD=20.86) | 0.001 |
| 0.922 | 0.904 | ||
| ACTa | |||
| TH (n=44, n=27) | 11.51 (SD=3.77) | 13.59 (SD=4.53) | 0.031 |
| MDI (n=59, n=37) | 10.22 (SD=4.36) | 13.24 (SD=4.25) | <0.001 |
| All (n=103, n=64) | 10.77 (SD=4.14) | 13.39 (SD=4.34) | <0.001 |
| 0.067 | 0.753 | ||
| Reliever usea | |||
| TH (n=44, n=27) | 6.36 (SD=4.46) | 4.21 (SD=4.08) | 0.009 |
| MDI (n=59, n=37) | 7.82 (SD=3.42) | 5.14 (SD=3.71) | <0.001 |
| All (n=103, n=64) | 7.21 (SD=3.93) | 4.7441 (SD=3.87) | <0.001 |
| 0.144 | 0.345 |
Notes: aNot all patients reported their data at the follow-up visit.
Abbreviations: ACT, Asthma Control Test; FEV1%, forced expiratory volume in the first 1 second; MDI, metered dose inhaler; NA, not applicable; TH, turbuhaler.
Past inhaler technique education reported by study participants at baseline (n=103)
| TH (n=44) | MDI (n=59) | All (n=103) | ||
|---|---|---|---|---|
| Why did you choose to use this type of inhaler?, n (%) | 0.927 | |||
| Specialist advice | 42 (95.45%) | 56 (94.92%) | 98 (95.15%) | |
| Pharmacist advice | 1 (2.27%) | 1 (1.69%) | 2 (4.85%) | |
| Family advice | 1 (2.27%) | 2 (3.39%) | 3 (2.91%) | |
| Have you ever been provided with education or advice about how to use your inhaler? “Yes”, n (%) | 44 (100%) | 59 (100%) | 103 (100%) | NA |
| If yes, was this by: | 0.295 | |||
| Regular doctor | 0 (0.00%) | 3 (50.85%) | 3 (2.91%) | |
| Pharmacist | 1 (2.27%) | 0 (0.00%) | 1 (0.97%) | |
| Medical center | 0 (0.00%) | 1 (1.69%) | 1 (0.97%) | |
| Specialist | 5 (11.36%) | 3 (5.08%) | 8 (7.77%) | |
| Hospital clinic | 37 (84.09%) | 49 (83.08%) | 86 (83.50%) | |
| Other people | 1 (2.27%) | 3 (2.08%) | 4 (3.88%) | |
| If yes, what was the type of counseling?, n (%) | 0.147 | |||
| Verbal information | 22 (50.00%) | 33 (55.93%) | 55 (53.40%) | |
| Written information | 0 (0.00%) | 1 (1.69%) | 1 (0.97%) | |
| Physical demonstration | 19 (43.18%) | 15 (25.42%) | 34 (33.00%) | |
| Cannot recall | 3 (6.82%) | 10 (16.95%) | 13 (12.62%) | |
| If yes, when did you receive this information or advice?, n (%) | 0.263 | |||
| When you first got your inhaler | 36 (81.82%) | 37 (62.71%) | 73 (70.87%) | |
| After you started using your inhaler | 1 (2.27%) | 2 (3.40%) | 3 (2.91%) | |
| At some other time | 4 (9.09%) | 6 (10.17%) | 10 (9.71%) | |
| After requesting information on how to use your inhaler | 0 (0.00%) | 1(69%) | 1 (0.97%) | |
| Cannot recall | 3 (6.82%) | 13 (22.03%) | 16 (15.53%) | |
| Have you received any information or advice about how to use your inhaler in the last 12 months? “Yes”, n (%) | 3 (6.82%) | 10 (16.95%) | 13 (12.62%) | 0.126 |
| Has anyone ever checked the way you use your inhaler? “Yes”, n (%) | 3 (6.82%) | 4 (6.78%) | 7 (6.80%) | 0.994 |
| Do you think that you use your inhaler correctly?, n (%) | 8:21:11 | 3:22:43 | 11:34:49 | 0.022 |
| Do you like using your inhaler for your asthma management? “Yes”, n (%) | 32 (72.73%) | 48 (81.36%) | 80 (77.67%) | 0.298 |
| Do you have concerns with using your inhaler?, n (%) | 0.363 | |||
| No | 40 (90.90%) | 49 (83.05%) | 89 (86.40%) | |
| Corticosteroid phobia | 4 (9.09%) | 6 (10.17%) | 10 (9.71%) | |
| Bad taste | 0 (0.00%) | 3 (5.08%) | 3 (2.91%) | |
| Not effective | 0 (0.00%) | 1 (1.69%) | 1 (0.97%) | |
| Were you given over the counter medications by your pharmacist to help manage your asthma? “Yes”, n (%) | 9 (20.45%) | 13 (22.03%) | 22 (21.36%) | 0.847 |
| Do you use any herbal treatment for the management of your asthma? “Yes”, n (%) | 2 (4.55%) | 3 (5.08%) | 5 (4.85%) | 0.900 |
| Do you perform mouth rinsing after using your inhaler? “Yes”, n (%) | 12 (27.27%) | 15 (25.42%) | 27 (26.21%) | 0.833 |
| Do you suffer from oral thrush? “Yes”, n (%) | 1 (2.27%) | 6 (10.17%) | 7 (6.80%) | 0.152 |
| Have you heard of the breathing exercise to manage your asthma? “Yes”, n (%) | 1 (2.27%) | 2 (3.39%) | 3 (2.91%) | 0.739 |
| Do you have an asthma action plan | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | NA |
| Have you ever used a PFM before? “Yes”, n (%) | 3 (6.82%) | 1 (1.69%) | 4 (3.88%) | 0.183 |
Abbreviations: ACT, Asthma Control Test; FEV1%, forced expiratory volume in the first 1 second; MDI, metered dose inhaler; NA, not applicable; PFM, peak flow meter; TH, turbuhaler.
Figure 2Proportion of patients categorized according to asthma severity at baseline (TH, n=44; MDI, n=59) and follow-up (TH, n=27; MDI, n=37).
Abbreviations: MDI, metered dose inhaler; TH, turbuhaler.
Summary of the regression model obtained for the dependent variable, ACT score change across the study (n=64)
| Variable | β | ||
|---|---|---|---|
| Inhaler type (TH or MDI) | −0.039 | −0.476 | 0.636 |
| Age | −0.036 | −0.402 | 0.689 |
| Gender | −0.071 | −0.851 | 0.398 |
| Change in inhaler technique mean score | 0.050 | 0.596 | 0.554 |
| ACT scores at baseline | −0.507 | −6.039 | <0.001 |
| Change in FEV1% across the study | 0.604 | 7.375 | <0.001 |
Notes: This table shows the output from a multivariable regression analysis of Asthma Control Test (ACT) score improvement across the study (overall fit of the model was R2=0.631, p<0.001).
Abbreviations: β, standardized regression coefficient; FEV1%, forced expiratory volume in the first 1 second; MDI, metered dose inhaler; TH, turbuhaler.
Figure 3Proportion of metered dose inhaler users who demonstrated each step in the inhaler technique checklist correctly at baseline and follow-up (n=59).
Figure 4Proportion of turbuhaler users who demonstrated each step in the inhaler technique checklist correctly at baseline and follow-up (n=44).